Navigation Links
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
Date:10/26/2009

of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

In addition to PF-4523655, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation. Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals for the structure of these products.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent in eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.         The Ruth Group (investors / media)
    Juliana Friedman                    Sara Ephraim / Janine McCargo
    +972 89 30 5111                     (646) 536-7002 / 7033
    jfriedman@quarkpharma.com           sephraim@theruthgroup.com
                                        jmccargo@theruthgroup.com

SOURCE Quark Pharmaceuticals, Inc.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 20, 2015 Research and Markets( ... "Guide to Prepare Application Dossiers for Oversea ... Edition) " report to their offering. ... of segment market of the most growth potentiality, ... device manufacturers and producers to penetrate such market. ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
(Date:5/22/2015)... CITY, Calif. , May 22, 2015 ... pharmaceutical company focused on the development and commercialization of ... pain, today announced that interim chief executive officer ... Healthcare Conference and chief financial officer Tim Morris ... Conference. Details of the two presentations are as follows: ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... LUCCA, Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron ... the,treatment of musculoskeletal, metabolic and cancer-related,diseases, today ... that demonstrated the ability of the compound ... mice and in murine models of,muscular dystrophy. ...
... WIRE)--May 14, 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the ... new Sular formulation. The study,results showed that the ... Sular. The new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented ... dose of Sular for each of its,current doses. ...
Cached Medicine Technology:Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4
(Date:5/22/2015)... Knoxville, TN (PRWEB) May 22, 2015 Power ... Andrew Drobeck for the 2015 race season. Drobeck is in ... also serves as a firefighter with the Missoula Fire Department ... and became a Pro in 2014. During his career, he ... as a Pro, Drobeck recorded top 10 finishes in all ...
(Date:5/22/2015)... The dentist in West ... they are now offering complimentary consultations to patients ... At consultations, patients can discuss their candidacy for ... treatments can achieve and whether alternative options are ... appointment. If treatments are chosen, patients can start ...
(Date:5/22/2015)... A Phase 3 French study, ... of Clinical Oncology (ASCO)’s annual meeting at the ... those patients who received bevacizumab in addition to ... (Avastin® Genentech, Inc.) is an antibody that blocks ... routinely used to treat many other cancers, including ...
(Date:5/22/2015)... AZ (PRWEB) May 22, 2015 In ... Olympics, Parker and Sons is offering to donate $5 ... installing an AC unit or water softening system. Customers ... behalf; Parker and Sons gets business; and the Special ... , The Special Olympics helps over 4.4 million athletes, ...
(Date:5/22/2015)... May 22, 2015 A new program ... experts in the field of Physical Therapy. , ... takes the mystery out of physical therapy and discusses ... of motion for a variety of ailments and injuries. ... a personalized exercise plan that enhances daily activities such ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... 12 The following was,issued today by the ... (NQF) Implementation Conference on Care,Coordination and 2008 Spring ... http://www.qualityforum.org ., March 26: Spring Membership Meeting. ... membership and leaders of the National Priorities,Partners, a ...
... who use ibuprofen for arthritis pain or other conditions ... second stroke undermine aspirins ability to act as an ... shown. , In a cohort of patients seen by ... 28 patients were identified as taking both aspirin and ...
... Impact Patient Health and Financial ... Performance of Pharmaceutical Companies, NEW YORK and LONDON, March ... per year and causing an,estimated 125,000 deaths per year in ... healthcare industry. Eularis has,responded to this problem with a new ...
... physicians from using Avastin, researchers say , , WEDNESDAY, March 12 ... cause kidney damage by doing what it,s supposed to -- ... whose generic name is bevacizumab, is the first member of ... off their blood supply. It does this by inhibiting the ...
... Downloadable ,Pocket, Films Help Increase Public Understanding ... 12 With the aging of the,population, ... epidemic,proportions by mid-century, creating massive and unsustainable ... families, and millions of lives,tragically lost to ...
... Race Central, the country,s,preeminent race timing organization, ... 5K run/walk ( http://www.VigorLatino5K.com ) to be,held at ... March,29, 2008. The Vigor Latino 5K run/walk will ... to take part in a local run/walk Health ...
Cached Medicine News:Health News:National Quality Forum Spring Conference; Leaders in Healthcare Quality to Focus on National Priorities and Care Coordination 2Health News:Ibuprofen destroys aspirin's positive effect on stroke risk 2Health News:Ibuprofen destroys aspirin's positive effect on stroke risk 3Health News:Eularis Exposes Hidden Barriers to Patient Adherence With New Pharmaceutical Industry Report 2Health News:Eularis Exposes Hidden Barriers to Patient Adherence With New Pharmaceutical Industry Report 3Health News:Doctors See How Cancer Drug Can Damage Kidneys 2Health News:Doctors See How Cancer Drug Can Damage Kidneys 3Health News:New Tools Boost Alzheimer's Awareness 2Health News:New Tools Boost Alzheimer's Awareness 3Health News:Race Central Launches Vigor Latino 5K Run/Walk, Promoting Hispanic Health, Fun and Fitness 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: